Synthesis and biological activity of a novel C4-C6 bridged paclitaxel analog

Tetrahedron

Volumn 55, Issue 32, 1999, Pages 9707-9716

  Yuan, Haiqing ^a   Kingston, David G I ^a   Sackett, Dan L ^b   Hamel, Ernest ^b  

^a VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Biologically active compounds; Lactonization; Macrocycles; Taxoids

Indexed keywords

PACLITAXEL; PACLITAXEL DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MICROTUBULE ASSEMBLY; PRIORITY JOURNAL;

EID: 0033529688     PISSN: 00404020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0040-4020(99)00552-9     Document Type: Article

References (27)

1. Present address: Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556.
2. For a review of the development and clinical utility of the taxane class of anticancer agents, see Rowinsky, E. K. Annu. Rev. Med. 1997, 48, 353-374.
3. For reviews of the chemistry and structure-activity relationships of paclitaxel see: (a) Kingston, D. G. I. Pharmac. Ther. 1991, 52, 1-34.
4. Kingston, D. G. I. Trends Biotechnol. 1994, 12, 222-227.
5. Chen, S.-H.; Farina, V. Paclitaxel structure-activity relationships and core skeletal rearrangements. In Taxane Anticancer Agents: Basic Science and Current Status; Georg, G. I.; Chen, T. T.; Ojima, I.; and Vyas, D. M., Eds.; ACS Symposium Series 583, American Chemical Society: Washington, DC, 1994; pp 247-261.
6. Georg, G. I.; Boge, T. C.; Cheruvallath, Z. S.; Clowers, J. S.; Harriman, G. C. B.; Hepperle, M.; Park, H. The medicinal chemistry of taxol. In Taxol: Science and Applications; Suffness, M.; Ed.; CRC Press, Inc.: Boca Raton, FL, 1995; pp 317-375.
7. Kingston, D. G. I. Recent advances in the chemistry and structure-activity relationships of paclitaxel. In Taxane Anticancer Agents: Basic Science and Current Status; George, G. I.; Chen, T. T.; Ojima, I.; and Vyas, D. M., Eds.; ACS Symposium Series 583, American Chemical Society: Washington, DC, 1994; pp 203-216.
8. Nicolaou, K. C.; Dai, W.-M.; Guy, R. K.; Angew. Chem. Int. Ed. Engl. 1994, 33, 15-44.
9. Vyas, D. M.; Kadow, J. F. In Progress in Medicinal Chemistry; Ellis, G. P.; Luscombe, D. K., Ed.; Eisevier Science B. V.: Amsterdam, 1995; Vol. 32; pp 289-337.
10. Guenard, D.; Gueritte-Voegelein, F.; Lavelle, F. Curr. Pharm. Design 1995, 1, 95-112.
11. Guenard, D.; Gueritte-Voegelein, F.; Potier, P. Acc. Chem. Res. 1993, 26, 160-167.
12. Schiff, P. B.; Fant, J.; Horwitz, S. B. Nature 1979, 277:, 665-667.
13. Nogales, E.; Wolf, S. G.; Downing, K. H. J. Struct. Biol. 1997, 118, 119-127.
14. Nogales, E.; Wolf, S. G.; Downing, K. H. Nature 1998, 391, 199-203.
15. Rao, S.; Krauss, N. E.; Heerding, J. M.; Swindell, C. S.; Ringel, I.; Orr, G. A.; Horwitz, S. B. J. Biol. Chem. 1994, 269, 3132-3134.
16. Rao, S.; Orr, G. A.; Chaudhary, A. G.; Kingston, D. G. I.; Horwitz, S. B. J. Biol. Chem. 1995, 270, 20235-20238.
17. Han, Y.; Ghaudhary, A. G.; Chordia, M. D.; Sackett, D. L.; Perez-Ramirez, B.; Kingston, D. G. I.; Bane, S. Biochemistry 1996, 35, 14173-14183.
18. Ojima, I.; Kuduk, S. D.; Chakravarty, S.; Ourevitch, M.; Begue, J.-P. J. Am. Chem. Soc. 1997, 119, 5519-5527.
19. Vander Velde, D. G.; Georg, G. I.; Grunewald, G. L.; Gunn, C. W.; Mitscher, L. A. J. Am. Chem. Soc. 1993, 115, 11650-11651.
20. Chen, S.-H.; Wei, J.-M.; Long, B. H.; Fairchild, C. A.; Carboni, J.; Mamber, S. W.; Rose, W. C.; Johnston, K.; Casazza, A. M.; Kadow, J. F.; Farina, V.; Vyas, D.; Doyle, T. W. Bioorg. & Med. Chem. Lett. 1995, 5, 2741-2746.
21. Chen, S.-H. Tetrahedron Lett. 1996, 37, 3935-3938.
22. Liang, X.; Kingston, D. G. I.; Lin, C. M.; Hamel, E. Tetrahedron Lett. 1995, 36, 2901-2904.
23. Liang, X.; Kingston, D. G. I.; Long, B. H.; Fairchild, C. A.; and Johnston, K. A. Tetrahedron Lett. 1997, 53, 3441-3456.
24. Chaudhary, A. G.; Gharpure, M.; Rimoldi, J. M.; Chordia, M. D.; Gunatilaka, A. A. L.; Kingston, D. G. I.; Grover, S.; Lin, C. M.; Hamel, E. J. Am. Chem. Soc. 1994, 116, 4097.
25. For a similar example, see Datta, A.; Aube, J.; Georg, G. I.; Mitscher, L. A. Bioorg. Med. Chem. Lett. 1994, 4, 1831.
26. Various hypothetical bridged analogs were examined by changing the linker between C-4 and C-6 as well as the C-4 acyl moiety, the minimized energy was compared to determine the relative stability of the analogs. During the modeling studies, it was found that certain chains such as unsaturated di-acids or phenylene dialkyl di-acids at the C-4 position might be better than the glutaric acid in both terms of entropy (less degree of freedom) and product stability (less trans-annular interactions). Because of the unavailability of the appropriate reagents and the problems encountered in the C-4 acylation using the synthetic reagents, it was decided to simplify the question by choosing glutaric acid as the acyl source at C-4.
27. Kingston, D. G. I.; Chaudhary, A. G.; Chordia, M. D.; Gharpure, M.; Gunatilaka, A. A. L.; Higgs, P. I.; Rimoldi, J. M.; Samala, L.; Jagtap, P. G.; Giannakakou, P.; Jiang, Y. Q.; Lin, C. M.; Hamel, E.; Long, B. H.; Fairchild, C. A.; Johnston, K. A. J. Med. Chem. 1998, 41, 3715-3726.